Difference between revisions of "Quizartinib (Vanflyta)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
Line 10: | Line 10: | ||
*'''Code name:''' ASP2689 | *'''Code name:''' ASP2689 | ||
− | [[Category: | + | [[Category:Drugs]] |
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Revision as of 22:56, 13 June 2018
Mechanism of action
FLT3 inhibitor
Preliminary data
Acute myeloid leukemia
- Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10;31(29):3681-7. Epub 2013 Sep 3. link to original article PubMed
- Abstract: Jorge E. Cortes, Alexander E Perl, Hervé Dombret, Sabine Kayser, Björn Steffen, Philippe Rousselot, Giovanni Martinelli, Elihu H. Estey, Alan K Burnett, Guy Gammon, Denise Trone, Eugen Leo, and Mark J. Levis Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 48. link to abstract
Also known as
- Code name: ASP2689